Cancer of Unknown Primary Service

Similar documents
PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease

Cancer of Unknown Primary (CUP) Protocol

Cancer of Unknown Primary (CUP)

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO)

Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Cancer of Unknown Primary Network Site Specific Group. Clinical Guidelines

South Yorkshire, Bassetlaw and North Derbyshire Cancer Alliance

South West Strategic Clinical Network Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services

Greater Manchester Commissioning Hub: Cancer Programme. The ACE Programme. Wave 2 Multidisciplinary Diagnostic Centres

Unknown Primary Service for patients at Chesterfield Royal Hospital

Cancer of Unknown Primary

National Breast Cancer Audit next steps. Martin Lee

Manchester Cancer. Guidelines for Investigation and Management of Malignancy of Unknown Origin (MUO) / Cancer of Unknown Primary (CUP)

Greater Manchester Cancer: Guidelines for Investigation and Management of Malignancy of Unknown Origin (MUO) and Cancer of Unknown Primary (CUP)

Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases

Recognition and Referral of Suspected Cancer - NICE guidance and local initiatives

CUP Investigation and Management Guidelines V1 West Midlands SCN Acute Oncology, MSCC and CUP ERG /PJJ/

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

Testicular Germ Cell Cancer Explained

Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer

Bladder Cancer Guidelines

Recommendations for cross-sectional imaging in cancer management, Second edition

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

MSCC CARE PATHWAYS & CASE STUDIES. By Michael Balloch Spine CNS

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 5

Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review: Version No. 1.1 Supercedes 1.0 Links to other policies

SCOTTISH CANCER REFERRAL GUIDELINES REVIEW 2018

Cancer of Unknown Primary

Louisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust

Delivering 62 Day GP Cancer Waits in a Complex Landscape. Hannah Marder Cancer Manager University Hospitals Bristol

How a fully integrated Acute Oncology Service can benefit the busy medical unit

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Appendix 4 Urology Care Pathways

NICE BULLETIN Diagnosis & treatment of prostate cancer

LCA Lung Clinical Forum. 21 st October 2014

Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction

West Midlands Sarcoma Advisory Group

Clinical Biochemistry Department City Hospital

Faster Cancer Treatment Indicators: Use cases

Are We Ordering Tumor Markers Appropriately?

Guideline for the Management of Vulval Cancer

SOUTH THAMES CHILDREN S CANCER NETWORK GROUP. REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014

West Midlands Sarcoma Advisory Group

Specialist Palliative Care Service Referral Criteria and Guidance

National Optimal Lung Cancer Pathway

GP Guidelines for the Management of Adult Patients with Gynaecological Cancers 2012

Dr Hilary Williams. Consultant in Medical Oncology at Velindre Cancer Centre

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

PATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE

NICE Quality Standards and COF

Update on Management of Malignant Spinal Cord Compression. Heino Hugel Consultant in Palliative Medicine University Hospital Aintree

Quality Standards for Diagnosis and Treatment in Breast Units Across Greater Manchester

Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru

NICE guideline on Suspected cancer: recognition and referral (2015) Education package for GPs and Nurse Practitioners Case scenarios

A06/S(HSS)b Ex-vivo partial nephrectomy service (Adult)

National Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator

REFERRAL GUIDELINES: UROLOGY

Palliative care - the opportunities. Dr David Brooks Macmillan Consultant in Palliative Medicine Chesterfield Royal Hospital

Clinical guideline Published: 26 July 2010 nice.org.uk/guidance/cg104

INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)

Mesothelioma Outcomes, Research and Experience survey (MORE Survey).

Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122

Coversheet for Network Site Specific Group Agreed Documentation. Diagnosis and Staging Protocol

Cancer of Unknown Primary (CUP)

Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel

David Brooks Macmillan Consultant in Palliative Medicine

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

There are a number of national guidelines and performance standards which support the implementation of a straight to CT pathway.

Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R

The Virtual Lung Nodule Clinic

ADJUVANT CHEMOTHERAPY...

Aneurin Bevan University Health Board Breast Cancer and Pregnancy Guideline

Transperineal ultrasound-guided biopsy of the prostate gland

Cancer: NICE (symptom based)- what s new November 2016

MDT IMPROVEMENT PROJECT. Professor Muntzer Mughal, UCLH

Louisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust

National Optimal Lung Cancer Pathways. Dr Sadia Anwar Nottingham University Hospitals NHS Trust Clinical Lead for Lung Cancer

Diagnosis and Classification of Prostate Cancer

9/13/2017. Highgate Private Hospital & Whittington Health NHS Trust. London Cancer Urology Guidelines for Target Referrals. Urological Cancer Groups

Evaluation of Cancer Outcomes Barwon South West Registry

Urgent referral for suspected cancer in Scotland

One Stop Prostate Biopsy Protocol Author Consultation Date Approved

Community and Mental Health Services. Palliative Care. Criteria and

Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012

The Role of an Upper GI Clinical Nurse Specialist

NICE Guidance. Suspected Cancer in Adults COLORECTAL (2WW)

North of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary

Single Suspected Cancer Pathway Definitions pathway start date

Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy

Skull Base Tumour Service. The Multi-Disciplinary Team (MDT) Explained. Jan 2018 v1

Pulmonary Embolism Pathway

The European Board of Urology

NICaN Testicular Germ Cell Tumours SACT protocols

North of Scotland Cancer Network Clinical Management Guideline for Malignant Melanoma

STAGING AND FOLLOW-UP STRATEGIES

Guideline for the Diagnosis of Breast Cancer

Transforming Cancer Services for London

Transcription:

Cancer of Unknown Primary Service Dr Maurice Fernando Consultant In Specialist Palliative Care and CUP lead Doncaster and Bassetlaw Hospitals NHS FT Wakefield meeting -14-07-2016

CUP service CUP MDT Tuesday ( DRI) CUP clinic (Primary diagnostic) pilot Thursday/ runs along Oncology clinic (DRI) Telephonic discussion- Primary & secondary care South Yorkshire Guidelines for MUO/CUP CUP peer review July 2016

Cancer of Unknown Primary and Malignancy of Undefined Origin Assessment Checklist MUST DO for all patients Review History Cancer symptoms confirm absence of especially: o Haemoptysis / cough o Hematemesis /dysphagia o Haematuria / abnormal vaginal bleeding o Altered Bowel habit / malena / rectal bleeding Risk factors - especially o Smoking history: o Industrial chemicals/ asbestos exposure: Family history o Cancers especially breast cancer include age of onset: Comorbidities o Especially cardiac disease, renal or hepatic impairment: Confirm Performance Status (PS) o 0 - Asymptomatic (Fully active, able to carry on all predisease activities without restriction) o 1 - Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work) o 2 - Symptomatic, <50% in bed during the day (Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours) o 3 - Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours) o 4 - Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair) o 5 - Death Review Examination findings Confirm that examination has included o breast examination o genital examination o digital rectal examination including prostate assessment in males o lymph nodes examination - consider U/S guided or surgical biposy if abnormal Review investigations request where not performed as directed clinically Patients PS 0-3 FBC, U+E, LFTs, LDH, CRP, Urinalysis CT scan chest / abdomen / pelvis Specific presentations:in patients with isolated or multiple lytic bone lesions - Immunoglobulin levels & Bence Jones Symptom-directed endoscopy.only if significant local symptoms in women presenting with clinical or pathological features compatible with breast cancer - Mammography In men with a presentation compatible with germ cell tumour - Testicular ultrasound Marker tests in patients with presentations compatible with germ cell tumours (particularly those with mediastinal and / or retroperitoneal presentations) AFP and hcg In patients with presentations compatible with hepatocellular cancer AFP. in men with presentations compatible with prostate cancer (bone, nodal and or lung) PSA in women with presentations compatible with ovarian cancer (including those with inguinal node, chest, pleural, peritoneal or retroperitoneal presentations) CA125 Carefully interpret the results because of limited test specificity Upgrade and refer o Upgrade all patients immediately to the MDT Co-ordinators o Refer to AOS CNS DRI- 07789741129 Bassetlaw -07789746164 o Refer to the unknown primary team (Speak to Dr M Fernando CUP Lead and Specialist Palliative Care Consultant or Palliative Care Consultant colleages via switchboard)

GP referral of patients with Metastatic Malignancy of Undefined Primary Origin NICE guidance has recommended improving the pathway for Patients with Metastatic Malignancy of Undefined Primary Origin. In response to this Doncaster & Bassetlaw Hospital NHs Trust has refined the pathway for this previously poorly served group of patients. We are very pleased to announce the weekly Primary Diagnostic Clinic run by Dr.Maurice Fernando and CUP CNS Claire Garbutt and Lynda Pollard. There is also an Unknown Primary Multi Disciplinary Team weekly meetings where the investigation and management is discussed with a team of specialists including Oncologist, Pathologists, Radiologists, Physicians, Surgeons and Specialist Palliative care. The team also sees in-patients who present with metastatic malignancy with an aim of focussing investigations on those that are appropriate, managing investigation as much as possible as an outpatient, for those who are not suitable for oncological treatment fast tracking into palliative care and, where appropriate, supported discharge home at the earliest opportunity. GPs can refer directly into the Primary Investigation Clinic. Patients who are suitable for referral are those with metastatic malignancy on diagnostic imaging for whom there are no red flag symptoms or signs to direct to a site specific clinic. Those with red flag symptoms should still be referred to the appropriate site specific team (e.g. patients with liver metastases and rectal bleeding should be referred to colorectal.) There will be some patients in whom early investigation in primary care points to the primary and should be directed down established referral routes e.g. patients with bone metastases with a high PSA should be referred to Urology. Lymph nodes should be referred for biopsy before being labelled as metastatic and the established referral practice should be followed for these (e.g. Neck Nodes to ENT, Axillary Nodes in females to Breast assessment). Patients with bony lesions, brain metastasis or disseminated malignancy with no obvious primary site on initial investigation can be referred to the CUP service. Recent NICE guidance 2015 on Cancer explains about vague symptoms which follow a different pathway via Multidisciplinary Diagnostic centres in community rather than the CUP service. While one of the objectives of the NICE guidance is to get early Palliative Care and Oncology input into these patients cancer pathway, Dr Fernando will be acting in his role as Consultant Physician for Unknown Primary (although this will overlap with his role as Consultant in Palliative Medicine) so there need not be concern that patients will be confronted by a Palliative Care label when this is inappropriate. However the prognosis for this group of patients is generally poor (median survival less than two months) so identifying those for whom further investigation is not in their best interests and facilitating transition to a palliative care approach will be an important part of the role of the team. Details of how to access the Primary diagnostic clinic are available on the Trust Website. However, if you have any queries or questions about the new service, please so not hesitate to contact Dr. Fernando or CUP CNS on Tel (01302) 642882, through the hospital switchboard.

Suspected Cancer referral for Metastatic Malignant Disease of Unknown Primary Origin (two-week wait referral) In accordance with NICE Guidance Please FAX within 24 hours to Specialtist Palliative Care Office 01302 647243 Section 1: PATIENT INFORMATION (Please complete in BLOCK CAPITALS) SURNAME Date of Referral / / Date of Birth / / FIRST Name NHS Number Date patient unavailable in the next 14 days. MR MISS MRS MS OTHER M { } F { } ADDRESS Day time phone Mobile phone Language Interpreter Y N POST CODE: Transport Y N Ethnicity Section 2: Practice Information (Please use practice stamp if available) REFERRING GP Locum Y N Practice Address Telephone Post code: Fax E-mail address:

Section 3: CLINICAL INFORMATION (Please tick all applicable entries) Please enclose print outs of CURRENT medications, PAST MEDICAL HISTORY and RELEVANT IMAGING REPORTS Imaging suggestive of metastatic disease (and NO primary organ specific symptoms)* *If patient has a history of cancer please consider whether this is more likely to be a recurrence than a true unknown primary cancer. Patients with suspected recurrence should be referred back to the site specific team. [ ] USS: Specify site [ ] CT scan: [ ] Chest, abdomen and pelvis [ ] Chest and abdomen [ ] MRI: Specify site Symptoms [ ] Progressive unintentional weight loss [ ] anorexia [ ] Pain: Specify site [ ] other: Further Information** **The referral CANNOT be made unless ALL these are completed Current WHO Performance Status of patient (please tick one) [ ] 0 Able to carry out normal activity without restriction [ ] 1 Restricted in physical strenuous activity but ambulatory and able to carry out light work [ ] 2 Ambulatory and capable of self care but unable to carry out any work: up and about for more than 50% waking hours [ ] 3 Capable only of limited self care; confined to bed or chair for more than 50% waking hours [ ] 4 Completely disabled; cannot carry out any self-care; totally confined to bed or chair [ ] Patient aware of suspected diagnosis of cancer [ ] Patient understands that further tests may be required AND is willing to accept these [ ] Patient is fit enough to undergo further tests AND for consideration of treatment if cancer confirmed If your patient does not meet any of these criteria, or if the patient has severe symptoms, please contact the upper GI team to discuss the referral. Contacts numbers are included in Section 5 on this form. INVESTIGATIONS MEDICAL HISTORY KNOWN ALLERGIES AND MEDICATION

2015-16 48 patients in CUP MDT 4-histological proven diagnosis of CUP-Oncologist 4-histological confirmed primary site- site specific team 10-radiological diagnosis site specific team 36 MUO Symptomatic and Palliative care support 5-died prior to discussion 4-no cancer

March 2016- to date-pilot 20 patients discussed at CUP MDT 2 referred directly from primary care 3 seen in CUP clinic 11 confirmed primary 4 confirmed CUP/MUO

Future Pilot to continue ~ 6-9 months Job plans to be reviewed Audit-local/network Education/ raising profile- GP ( TARGET& BEST ) Patient/carer survey

Thank you for listening Questions